USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$667.85M
Market Cap
-
P/E Ratio
-0.56
EPS
$5.95
52 Week High
$0.46
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Total Assets | $441M |
| Total Current Assets | $396M |
| Cash And Cash Equivalents At Carrying Value | $99M |
| Cash And Short Term Investments | $99M |
| Inventory | - |
| Current Net Receivables | $2.4M |
| Total Non Current Assets | $45M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $259M |
| Other Current Assets | $35M |
| Other Non Current Assets | - |
| Total Liabilities | $39M |
| Total Current Liabilities | $36M |
| Current Accounts Payable | $3.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $765K |
| Total Non Current Liabilities | $3.2M |
| Capital Lease Obligations | $3.2M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $3.2M |
| Other Current Liabilities | $31M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$995M |
| Treasury Stock | - |
| Retained Earnings | -$1.2B |
| Common Stock | $29K |
| Common Stock Shares Outstanding | $98M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$126M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $5.4M |
| Capital Expenditures | $30M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $20M |
| Cashflow From Financing | $144M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$163M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
ProKidney Corp. is an innovative biotechnology company headquartered in Winston-Salem, North Carolina, specializing in transformative solutions for chronic kidney disease (CKD). The firm is pioneering cell-based therapies aimed at restoring kidney function and improving the quality of life for patients afflicted by this widespread ailment. With a robust pipeline of development initiatives and a commitment to advancing renal health, ProKidney is strategically positioned in the biopharmaceutical sector, making it an attractive opportunity for institutional investors seeking to drive meaningful healthcare advancements.